Back
pdf
Journal article

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

  • Anz, David Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Germany - Department of Gastroenterology Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Germany
  • Kruger, S. Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Germany
  • Haubner, S. Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Germany
  • Rapp, Moritz Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Germany
  • Bourquin, Carole Chair of Pharmacology, Department of Medicine, University of Fribourg, Switzerland
  • Endres, Stefan Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Germany
Show more…
    01.06.2014
Published in:
  • Diabetes, Obesity and Metabolism. - 2014, vol. 16, no. 6, p. 569–572
DPP IV inhibitor
drug mechanism
pharmacology
type 2 diabetes
English Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic regulation, DPP-IV also plays a role in the immune system. Whether the DPP-IV inhibitors sitagliptin, vildagliptin or saxagliptin impair immune responses is, however, currently unknown. Here, we investigated the effect of these agents on both innate and adaptive immunity. We found that the DPP-IV inhibitors did not affect the innate immune response induced by Toll-like receptor (TLR) ligands, as cytokine secretion and induction of co-stimulatory molecules by human blood mononuclear cells was not impaired. Furthermore, proliferation of T cells and suppressive function of regulatory T cells was preserved. Mice treated with vildagliptin showed normal cytokine production, immune cell activation and lymphocyte trafficking upon TLR activation. Thus, crucial immunological parameters remain unaffected upon treatment with DPP-IV inhibitors, a fact that is reassuring with respect to safety of these drugs.
Faculty
Faculté des sciences et de médecine
Department
Département de Médecine
Language
  • English
Classification
Medicine
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/303815
Statistics
Document views: 44 File downloads:
  • bou_dis.pdf: 144